One2Treat Secures Funding To Accelerate Platform Development And Expands Offices To Support Rapid Growth

One2Treat, led by CEO Sébastien Coppe, has secured undisclosed funding to expand its operations and further develop its platform.

The company provides software and patient-centered methodologies that help sponsors integrate the patient’s voice into early trial design, endpoint selection, and treatment value assessment, supporting meaningful clinical trials, informed decision-making, and stronger regulatory discussions.

This investment comes after the deployment of the One2Treat Insights module across multiple live projects and the recent launch of the One2Treat Voice module.

Read Also - Ketryx Secures $39M To Advance AI Compliance In Life Sciences

"The new space provides a larger, more modern and collaborative environment for the expanding team, fostering innovation and facilitating closer partnerships with key academic and industry stakeholders." - Marc Buyse, Founder One2Treat

The funding will accelerate the development and scaling of One2Treat’s cloud-based platform, which consolidates diverse patient-focused outcomes into a comprehensive assessment of treatment effects, providing clearer insights into Net Treatment Benefit.

It supports clinical development decisions while also highlighting the medical value of new treatments during regulatory, HTA, and commercialization processes.

"Based on multiple recent successes, our shareholders were keen to accelerate the investment in our platform development. In addition, we offered every employee the opportunity to become a shareholder, and all chose to take part, highlighting a deep, shared commitment to our mission of putting patient voices at the center of clinical research." Sébastien Coppe, CEO, One2Treat

About One2Treat

One2Treat transforms how biopharmaceutical companies design and interpret clinical trials by integrating the patient’s voice. Its software platform and patient-centered methodologies guide trial design, endpoint selection, and treatment value assessment, enabling meaningful trials, informed decisions, stronger regulatory discussions, and faster market access.